Health and Fitness Health and Fitness
Thu, April 19, 2012
Wed, April 18, 2012
Tue, April 17, 2012
Mon, April 16, 2012
Sun, April 15, 2012
[ Sun, Apr 15th 2012 ] - Market Wire
DaVita Announces CFO Transition
Sat, April 14, 2012
Fri, April 13, 2012
Thu, April 12, 2012
Wed, April 11, 2012
Tue, April 10, 2012
Mon, April 9, 2012
Fri, April 6, 2012
Thu, April 5, 2012
[ Thu, Apr 05th 2012 ] - Market Wire
April 30, 2012
Wed, April 4, 2012

Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2012/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Thursday, April 12th 2012 at 14:36 GMT by Market Wire   Print publication without navigation


Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry... -- RICHMOND, Calif., April 12, 2012 /PRNewswire/ --

Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference

[ ]

RICHMOND, Calif., April 12, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 1:30 pm ET on Friday, April 20, 2012, at the Future Leaders in the Biotech Industry Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section [ http://investor.sangamo.com/index.cfm ] under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ]

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 

SOURCE Sangamo BioSciences, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.sangamo.com ]


Publication Contributing Sources